Drug Profile
BAM 1602
Alternative Names: BAM-1602Latest Information Update: 25 Feb 2008
Price :
$50
*
At a glance
- Originator Maruko Seiyaku
- Class Antihypertensives; Heart failure therapies; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 06 Aug 1998 No-Development-Reported for Heart failure in Japan (unspecified route)
- 18 May 1995 Preclinical development for Heart failure in Japan (unspecified route)